Premium
Combination Immunotherapy: A Dual Immunotherapy Nanoparticle Improves T‐Cell Activation and Cancer Immunotherapy (Adv. Mater. 25/2018)
Author(s) -
Mi Yu,
Smith Christof C.,
Yang Feifei,
Qi Yanfei,
Roche Kyle C.,
Serody Jonathan S.,
Vincent Benjamin G.,
Wang Andrew Z.
Publication year - 2018
Publication title -
advanced materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.707
H-Index - 527
eISSN - 1521-4095
pISSN - 0935-9648
DOI - 10.1002/adma.201870182
Subject(s) - immunotherapy , cancer immunotherapy , agonist , materials science , cancer research , immune checkpoint , t cell , blockade , cancer , immune system , medicine , immunology , receptor
The combination of checkpoint blockade and T cell agonist is poised to become the next generation of cancer immunotherapy treatment. In article number 1706098 , Andrew Z. Wang and co‐workers report a new strategy to improve the efficacy of such regimens. They engineer dual‐immunotherapy nanoparticles (DINPs) that contain both an immune checkpoint inhibitor and a T cell agonist to improve simultaneous signaling in T cells and demonstrate that the DINPs are significantly more effective than their free antibody counterparts.